MedTrace Logo

DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population

NCT01331707 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1811

Last updated 2015-07-28

No results posted yet for this study

Summary

The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity but there are further demands on DES performance. Such demands are an optimized performance in very challenging coronary lesions; third generation DES were developed in an effort to further improve DES performance in such challenging lesions. Two CE-certified third generation DES (Resolute Integrity and Promus Element stents) are currently available; there are no data that indicate an advantage of one of these DES over the other.

Conditions

Interventions

DEVICE

Resolute Integrity (Zotarolimus-eluting stent)

Third generation drug-eluting stent

DEVICE

Promus Element (Everolimus-eluting stent)

Third generation drug-eluting stent

Sponsors & Collaborators

  • Foundation of Cardiovascular Research and Education Enschede

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-12-31
Completion
2013-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01331707 on ClinicalTrials.gov